CStone Pharmaceuticals
CStone Pharmaceuticals (2616.HK) Stock Competitors & Peer Comparison
See (2616.HK) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| 2616.HK | HK$5.44 | -32.42% | 8.7B | -15.11 | -HK$0.36 | N/A |
| 6160.HK | HK$171.50 | -3.00% | 231.3B | 64.23 | HK$2.67 | N/A |
| 2269.HK | HK$34.62 | +3.84% | 143.4B | 25.84 | HK$1.34 | N/A |
| 1801.HK | HK$80.90 | -2.94% | 140.3B | 149.81 | HK$0.54 | N/A |
| 9926.HK | HK$115.90 | -1.86% | 106.6B | -81.62 | -HK$1.42 | N/A |
| 6990.HK | HK$435.40 | -5.76% | 101.5B | -224.43 | -HK$1.94 | N/A |
| 1177.HK | HK$4.95 | -0.80% | 88.5B | 33.00 | HK$0.15 | +1.82% |
| 3759.HK | HK$17.25 | -1.54% | 47.1B | 15.68 | HK$1.10 | +1.27% |
| 1530.HK | HK$18.52 | +0.11% | 46.3B | 4.68 | HK$3.96 | +1.35% |
| 9995.HK | HK$78.40 | -5.14% | 43.4B | 52.62 | HK$1.49 | N/A |
Stock Comparison
2616.HK vs 6160.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 6160.HK has a market cap of 231.3B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 6160.HK trades at HK$171.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 6160.HK's P/E ratio is 64.23. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 6160.HK's ROE of +0.12%. Regarding short-term risk, 2616.HK is more volatile compared to 6160.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 6160.HK's competition here
2616.HK vs 2269.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 2269.HK has a market cap of 143.4B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 2269.HK trades at HK$34.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 2269.HK's P/E ratio is 25.84. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2269.HK's ROE of +0.11%. Regarding short-term risk, 2616.HK is more volatile compared to 2269.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2269.HK's competition here
2616.HK vs 1801.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 1801.HK has a market cap of 140.3B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 1801.HK trades at HK$80.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 1801.HK's P/E ratio is 149.81. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 1801.HK's ROE of +0.05%. Regarding short-term risk, 2616.HK is more volatile compared to 1801.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 1801.HK's competition here
2616.HK vs 9926.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 9926.HK has a market cap of 106.6B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 9926.HK trades at HK$115.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 9926.HK's P/E ratio is -81.62. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 9926.HK's ROE of -0.14%. Regarding short-term risk, 2616.HK is more volatile compared to 9926.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 9926.HK's competition here
2616.HK vs 6990.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 6990.HK has a market cap of 101.5B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 6990.HK trades at HK$435.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 6990.HK's P/E ratio is -224.43. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 6990.HK's ROE of N/A. Regarding short-term risk, 2616.HK is more volatile compared to 6990.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 6990.HK's competition here
2616.HK vs 1177.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 1177.HK has a market cap of 88.5B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 1177.HK trades at HK$4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 1177.HK's P/E ratio is 33.00. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 1177.HK's ROE of +0.07%. Regarding short-term risk, 2616.HK is more volatile compared to 1177.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 1177.HK's competition here
2616.HK vs 3759.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 3759.HK has a market cap of 47.1B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 3759.HK trades at HK$17.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 3759.HK's P/E ratio is 15.68. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 3759.HK's ROE of +0.11%. Regarding short-term risk, 2616.HK is more volatile compared to 3759.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 3759.HK's competition here
2616.HK vs 1530.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 1530.HK has a market cap of 46.3B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 1530.HK trades at HK$18.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 1530.HK's P/E ratio is 4.68. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 1530.HK's ROE of +0.39%. Regarding short-term risk, 2616.HK is more volatile compared to 1530.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 1530.HK's competition here
2616.HK vs 9995.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 9995.HK has a market cap of 43.4B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 9995.HK trades at HK$78.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 9995.HK's P/E ratio is 52.62. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 9995.HK's ROE of +0.42%. Regarding short-term risk, 2616.HK is more volatile compared to 9995.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 9995.HK's competition here
2616.HK vs 2696.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 2696.HK has a market cap of 34.4B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 2696.HK trades at HK$63.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 2696.HK's P/E ratio is 36.14. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2696.HK's ROE of +0.24%. Regarding short-term risk, 2616.HK is more volatile compared to 2696.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2696.HK's competition here
2616.HK vs 6821.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 6821.HK has a market cap of 32.3B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 6821.HK trades at HK$89.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 6821.HK's P/E ratio is 24.88. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 6821.HK's ROE of +0.06%. Regarding short-term risk, 2616.HK is more volatile compared to 6821.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 6821.HK's competition here
2616.HK vs 1877.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 1877.HK has a market cap of 27.3B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 1877.HK trades at HK$19.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 1877.HK's P/E ratio is -19.95. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 1877.HK's ROE of -0.11%. Regarding short-term risk, 2616.HK is more volatile compared to 1877.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 1877.HK's competition here
2616.HK vs 1548.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 1548.HK has a market cap of 26.6B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 1548.HK trades at HK$12.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 1548.HK's P/E ratio is -6.31. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 1548.HK's ROE of -0.13%. Regarding short-term risk, 2616.HK is more volatile compared to 1548.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 1548.HK's competition here
2616.HK vs 2096.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 2096.HK has a market cap of 26.2B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 2096.HK trades at HK$10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 2096.HK's P/E ratio is 16.27. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2096.HK's ROE of +0.16%. Regarding short-term risk, 2616.HK is more volatile compared to 2096.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2096.HK's competition here
2616.HK vs 9606.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 9606.HK has a market cap of 18.5B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 9606.HK trades at HK$204.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 9606.HK's P/E ratio is -4.45. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 9606.HK's ROE of -1.64%. Regarding short-term risk, 2616.HK is more volatile compared to 9606.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 9606.HK's competition here
2616.HK vs 2315.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 2315.HK has a market cap of 18.1B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 2315.HK trades at HK$44.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 2315.HK's P/E ratio is 89.40. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2315.HK's ROE of +0.11%. Regarding short-term risk, 2616.HK is more volatile compared to 2315.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2315.HK's competition here
2616.HK vs 2162.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 2162.HK has a market cap of 17.9B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 2162.HK trades at HK$60.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 2162.HK's P/E ratio is -27.44. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2162.HK's ROE of -0.17%. Regarding short-term risk, 2616.HK is more volatile compared to 2162.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2162.HK's competition here
2616.HK vs 7666.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 7666.HK has a market cap of 17.3B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 7666.HK trades at HK$15.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 7666.HK's P/E ratio is -38.46. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 7666.HK's ROE of +2.70%. Regarding short-term risk, 2616.HK is more volatile compared to 7666.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 7666.HK's competition here
2616.HK vs 9969.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 9969.HK has a market cap of 17.2B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 9969.HK trades at HK$11.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 9969.HK's P/E ratio is 26.20. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 9969.HK's ROE of +0.10%. Regarding short-term risk, 2616.HK is more volatile compared to 9969.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 9969.HK's competition here
2616.HK vs 9688.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 9688.HK has a market cap of 15.3B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 9688.HK trades at HK$13.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 9688.HK's P/E ratio is -10.20. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 9688.HK's ROE of -0.24%. Regarding short-term risk, 2616.HK is more volatile compared to 9688.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 9688.HK's competition here
2616.HK vs 2617.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 2617.HK has a market cap of 14.2B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 2617.HK trades at HK$35.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 2617.HK's P/E ratio is -40.75. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2617.HK's ROE of N/A. Regarding short-term risk, 2616.HK is more volatile compared to 2617.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2617.HK's competition here
2616.HK vs 6855.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 6855.HK has a market cap of 14B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 6855.HK trades at HK$37.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 6855.HK's P/E ratio is -9.32. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 6855.HK's ROE of -1.24%. Regarding short-term risk, 2616.HK is more volatile compared to 6855.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 6855.HK's competition here
2616.HK vs 1672.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 1672.HK has a market cap of 12.5B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 1672.HK trades at HK$11.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 1672.HK's P/E ratio is -27.44. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 1672.HK's ROE of -0.19%. Regarding short-term risk, 2616.HK is more volatile compared to 1672.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 1672.HK's competition here
2616.HK vs 9887.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 9887.HK has a market cap of 12.1B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 9887.HK trades at HK$60.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 9887.HK's P/E ratio is -43.29. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 9887.HK's ROE of N/A. Regarding short-term risk, 2616.HK is more volatile compared to 9887.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 9887.HK's competition here
2616.HK vs 1952.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 1952.HK has a market cap of 10.7B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 1952.HK trades at HK$30.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 1952.HK's P/E ratio is -29.48. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 1952.HK's ROE of -0.07%. Regarding short-term risk, 2616.HK is more volatile compared to 1952.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 1952.HK's competition here
2616.HK vs 6872.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 6872.HK has a market cap of 10.6B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 6872.HK trades at HK$202.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 6872.HK's P/E ratio is -59.06. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 6872.HK's ROE of -0.58%. Regarding short-term risk, 2616.HK is more volatile compared to 6872.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 6872.HK's competition here
2616.HK vs 2171.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 2171.HK has a market cap of 9.9B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 2171.HK trades at HK$17.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 2171.HK's P/E ratio is -82.38. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2171.HK's ROE of -0.11%. Regarding short-term risk, 2616.HK is more volatile compared to 2171.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2171.HK's competition here
2616.HK vs 2142.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 2142.HK has a market cap of 9.4B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 2142.HK trades at HK$11.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 2142.HK's P/E ratio is 11.85. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2142.HK's ROE of +0.17%. Regarding short-term risk, 2616.HK is more volatile compared to 2142.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2142.HK's competition here
2616.HK vs 9966.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 9966.HK has a market cap of 8B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 9966.HK trades at HK$8.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 9966.HK's P/E ratio is -59.21. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 9966.HK's ROE of -0.06%. Regarding short-term risk, 2616.HK is more volatile compared to 9966.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 9966.HK's competition here
2616.HK vs 2157.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 2157.HK has a market cap of 7.5B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 2157.HK trades at HK$4.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 2157.HK's P/E ratio is 24.59. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2157.HK's ROE of +0.24%. Regarding short-term risk, 2616.HK is more volatile compared to 2157.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2157.HK's competition here
2616.HK vs 6826.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 6826.HK has a market cap of 7.4B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 6826.HK trades at HK$18.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 6826.HK's P/E ratio is 14.80. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 6826.HK's ROE of +0.04%. Regarding short-term risk, 2616.HK is more volatile compared to 6826.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 6826.HK's competition here
2616.HK vs 0775.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 0775.HK has a market cap of 7B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 0775.HK trades at HK$0.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 0775.HK's P/E ratio is -36.50. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 0775.HK's ROE of -0.05%. Regarding short-term risk, 2616.HK is more volatile compared to 0775.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 0775.HK's competition here
2616.HK vs 2256.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 2256.HK has a market cap of 6.3B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 2256.HK trades at HK$9.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 2256.HK's P/E ratio is 95.20. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2256.HK's ROE of +0.11%. Regarding short-term risk, 2616.HK is more volatile compared to 2256.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2256.HK's competition here
2616.HK vs 1477.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 1477.HK has a market cap of 4.8B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 1477.HK trades at HK$5.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 1477.HK's P/E ratio is -25.91. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 1477.HK's ROE of -0.04%. Regarding short-term risk, 2616.HK is more volatile compared to 1477.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 1477.HK's competition here
2616.HK vs 2591.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 2591.HK has a market cap of 4.7B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 2591.HK trades at HK$10.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 2591.HK's P/E ratio is -11.34. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2591.HK's ROE of -0.39%. Regarding short-term risk, 2616.HK is more volatile compared to 2591.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2591.HK's competition here
2616.HK vs 2509.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 2509.HK has a market cap of 3.7B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 2509.HK trades at HK$16.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 2509.HK's P/E ratio is 10.12. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2509.HK's ROE of -0.32%. Regarding short-term risk, 2616.HK is more volatile compared to 2509.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2509.HK's competition here
2616.HK vs 1167.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 1167.HK has a market cap of 3.5B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 1167.HK trades at HK$4.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 1167.HK's P/E ratio is -20.45. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 1167.HK's ROE of -0.18%. Regarding short-term risk, 2616.HK is more volatile compared to 1167.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 1167.HK's competition here
2616.HK vs 6660.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 6660.HK has a market cap of 3B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 6660.HK trades at HK$2.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 6660.HK's P/E ratio is -3.77. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 6660.HK's ROE of -0.22%. Regarding short-term risk, 2616.HK is more volatile compared to 6660.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 6660.HK's competition here
2616.HK vs 3880.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 3880.HK has a market cap of 2.9B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 3880.HK trades at HK$20.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 3880.HK's P/E ratio is 11.04. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 3880.HK's ROE of N/A. Regarding short-term risk, 2616.HK is more volatile compared to 3880.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 3880.HK's competition here
2616.HK vs 1873.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 1873.HK has a market cap of 2.7B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 1873.HK trades at HK$1.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 1873.HK's P/E ratio is 18.29. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 1873.HK's ROE of +0.06%. Regarding short-term risk, 2616.HK is more volatile compared to 1873.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 1873.HK's competition here
2616.HK vs 1875.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 1875.HK has a market cap of 2.6B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 1875.HK trades at HK$3.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 1875.HK's P/E ratio is -22.50. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 1875.HK's ROE of -0.15%. Regarding short-term risk, 2616.HK is more volatile compared to 1875.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 1875.HK's competition here
2616.HK vs 6996.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 6996.HK has a market cap of 2.4B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 6996.HK trades at HK$3.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 6996.HK's P/E ratio is -8.89. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 6996.HK's ROE of -0.34%. Regarding short-term risk, 2616.HK is more volatile compared to 6996.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 6996.HK's competition here
2616.HK vs 2197.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 2197.HK has a market cap of 2.4B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 2197.HK trades at HK$1.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 2197.HK's P/E ratio is -10.17. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2197.HK's ROE of +0.11%. Regarding short-term risk, 2616.HK is more volatile compared to 2197.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2197.HK's competition here
2616.HK vs 2179.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 2179.HK has a market cap of 2.4B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 2179.HK trades at HK$4.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 2179.HK's P/E ratio is -3.34. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2179.HK's ROE of -1.37%. Regarding short-term risk, 2616.HK is more volatile compared to 2179.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2179.HK's competition here
2616.HK vs 2181.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 2181.HK has a market cap of 1.6B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 2181.HK trades at HK$0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 2181.HK's P/E ratio is 40.00. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2181.HK's ROE of +0.44%. Regarding short-term risk, 2616.HK is more volatile compared to 2181.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2181.HK's competition here
2616.HK vs 2511.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 2511.HK has a market cap of 1.5B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 2511.HK trades at HK$3.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 2511.HK's P/E ratio is -5.10. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2511.HK's ROE of -0.39%. Regarding short-term risk, 2616.HK is more volatile compared to 2511.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2511.HK's competition here
2616.HK vs 1521.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 1521.HK has a market cap of 1.5B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 1521.HK trades at HK$0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 1521.HK's P/E ratio is 24.00. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 1521.HK's ROE of +0.02%. Regarding short-term risk, 2616.HK is more volatile compared to 1521.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 1521.HK's competition here
2616.HK vs 6622.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 6622.HK has a market cap of 1.4B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 6622.HK trades at HK$2.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 6622.HK's P/E ratio is -5.89. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 6622.HK's ROE of -0.13%. Regarding short-term risk, 2616.HK is more volatile compared to 6622.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 6622.HK's competition here
2616.HK vs 3681.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 3681.HK has a market cap of 1.4B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 3681.HK trades at HK$1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 3681.HK's P/E ratio is -11.90. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 3681.HK's ROE of -0.28%. Regarding short-term risk, 2616.HK is more volatile compared to 3681.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 3681.HK's competition here
2616.HK vs 2487.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 2487.HK has a market cap of 1.3B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 2487.HK trades at HK$3.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 2487.HK's P/E ratio is -3.09. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2487.HK's ROE of -0.41%. Regarding short-term risk, 2616.HK is more volatile compared to 2487.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2487.HK's competition here
2616.HK vs 1541.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 1541.HK has a market cap of 1.3B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 1541.HK trades at HK$2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 1541.HK's P/E ratio is -4.90. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 1541.HK's ROE of -0.33%. Regarding short-term risk, 2616.HK is more volatile compared to 1541.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 1541.HK's competition here
2616.HK vs 9939.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 9939.HK has a market cap of 1.2B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 9939.HK trades at HK$2.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 9939.HK's P/E ratio is -4.90. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 9939.HK's ROE of -0.99%. Regarding short-term risk, 2616.HK is more volatile compared to 9939.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 9939.HK's competition here
2616.HK vs 6998.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 6998.HK has a market cap of 1B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 6998.HK trades at HK$1.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 6998.HK's P/E ratio is 7.15. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 6998.HK's ROE of +0.16%. Regarding short-term risk, 2616.HK is more volatile compared to 6998.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 6998.HK's competition here
2616.HK vs 2898.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 2898.HK has a market cap of 1B. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 2898.HK trades at HK$6.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 2898.HK's P/E ratio is -10.49. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2898.HK's ROE of -0.17%. Regarding short-term risk, 2616.HK is more volatile compared to 2898.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2898.HK's competition here
2616.HK vs 1228.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 1228.HK has a market cap of 926.1M. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 1228.HK trades at HK$2.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 1228.HK's P/E ratio is 72.67. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 1228.HK's ROE of -0.04%. Regarding short-term risk, 2616.HK is more volatile compared to 1228.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 1228.HK's competition here
2616.HK vs 2496.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 2496.HK has a market cap of 863.1M. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 2496.HK trades at HK$4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 2496.HK's P/E ratio is -8.43. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2496.HK's ROE of +4.85%. Regarding short-term risk, 2616.HK is more volatile compared to 2496.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2496.HK's competition here
2616.HK vs 2137.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 2137.HK has a market cap of 836.6M. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 2137.HK trades at HK$1.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 2137.HK's P/E ratio is -3.22. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2137.HK's ROE of -0.09%. Regarding short-term risk, 2616.HK is more volatile compared to 2137.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2137.HK's competition here
2616.HK vs 1244.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 1244.HK has a market cap of 818.9M. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 1244.HK trades at HK$3.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 1244.HK's P/E ratio is -4.01. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 1244.HK's ROE of -0.27%. Regarding short-term risk, 2616.HK is more volatile compared to 1244.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 1244.HK's competition here
2616.HK vs 2126.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 2126.HK has a market cap of 812.1M. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 2126.HK trades at HK$1.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 2126.HK's P/E ratio is -1.26. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2126.HK's ROE of -0.75%. Regarding short-term risk, 2616.HK is more volatile compared to 2126.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2126.HK's competition here
2616.HK vs 2185.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 2185.HK has a market cap of 707.1M. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 2185.HK trades at HK$3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 2185.HK's P/E ratio is -8.82. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2185.HK's ROE of -0.15%. Regarding short-term risk, 2616.HK is more volatile compared to 2185.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2185.HK's competition here
2616.HK vs 6628.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 6628.HK has a market cap of 681.9M. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 6628.HK trades at HK$1.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 6628.HK's P/E ratio is -2.81. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 6628.HK's ROE of -0.28%. Regarding short-term risk, 2616.HK is more volatile compared to 6628.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 6628.HK's competition here
2616.HK vs 2257.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 2257.HK has a market cap of 576.1M. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 2257.HK trades at HK$5.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 2257.HK's P/E ratio is -4.48. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 2257.HK's ROE of +1.92%. Regarding short-term risk, 2616.HK is more volatile compared to 2257.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 2257.HK's competition here
2616.HK vs 0690.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 0690.HK has a market cap of 531.4M. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 0690.HK trades at HK$0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 0690.HK's P/E ratio is 4.45. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 0690.HK's ROE of +0.23%. Regarding short-term risk, 2616.HK is more volatile compared to 0690.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 0690.HK's competition here
2616.HK vs 6978.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 6978.HK has a market cap of 369.7M. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 6978.HK trades at HK$0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 6978.HK's P/E ratio is -1.47. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 6978.HK's ROE of +2.93%. Regarding short-term risk, 2616.HK is more volatile compared to 6978.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 6978.HK's competition here
2616.HK vs 8158.HK Comparison June 2026
2616.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2616.HK stands at 8.7B. In comparison, 8158.HK has a market cap of 117.1M. Regarding current trading prices, 2616.HK is priced at HK$5.44, while 8158.HK trades at HK$0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2616.HK currently has a P/E ratio of -15.11, whereas 8158.HK's P/E ratio is 4.28. In terms of profitability, 2616.HK's ROE is -0.65%, compared to 8158.HK's ROE of +0.87%. Regarding short-term risk, 2616.HK is more volatile compared to 8158.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2616.HK.Check 8158.HK's competition here